✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Bafna Pharmaceuticals Ltd.

BAFNAPH

Market Cap
₹180 Cr.
P/E
41.81

Bafna Pharmaceuticals Ltd.

  • Bafna Pharma
  • Krebs Biochem.&Inds
  • Bal Pharma
FAQs on Bafna Pharmaceuticals Ltd. Shareprice

Bafna Pharma has given better returns compared to its competitors.
Bafna Pharma has grown at ~14.35% over the last 7yrs while peers have grown at a median rate of 1.0%

Bafna Pharma is not expensive.
Latest PE of Bafna Pharma is 40.74, while 3 year average PE is 90.36.
Also latest EV/EBITDA of Bafna Pharma is 15.48 while 3yr average is 26.69.

View FAQ's On Business
Growth Table
  • Bafna Pharmaceuticals Ltd.
  • Krebs Biochem.&Inds
  • Bal Pharma
Balance Sheet
  • Bafna Pharmaceuticals Ltd.
  • Krebs Biochem.&Inds
  • Bal Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Bafna Pharmaceuticals Ltd.
  • Krebs Biochem.&Inds
  • Bal Pharma
Cash Flow
  • Bafna Pharmaceuticals Ltd.
  • Krebs Biochem.&Inds
  • Bal Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Bafna Pharmaceuticals Ltd.
  • Krebs Biochem.&Inds
  • Bal Pharma
Quarterly Results
  • Bafna Pharmaceuticals Ltd.
  • Krebs Biochem.&Inds
  • Bal Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Bafna Pharmaceuticals Ltd. Financials

Balance sheet of Bafna Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Bafna Pharma is increasing.
Latest debt of Bafna Pharma is ₹21.6 Crs as of Mar-24.
This is greater than Mar-23 when it was ₹7.31 Crs.

No, profit is decreasing.
The profit of Bafna Pharma is ₹4.3 Crs for TTM, ₹7.35 Crs for Mar 2024 and ₹11.34 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Bafna Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech